This company has been marked as potentially delisted and may not be actively trading. RXi Pharmaceuticals (RXII) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RXII vs. OSTX, EGRX, ELYM, MRNS, HILS, ALLK, CARA, NNVC, IBIO, and MEShould you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include OS Therapies (OSTX), Eagle Pharmaceuticals (EGRX), Eliem Therapeutics (ELYM), Marinus Pharmaceuticals (MRNS), Hillstream BioPharma (HILS), Allakos (ALLK), Cara Therapeutics (CARA), NanoViricides (NNVC), iBio (IBIO), and 23andMe (ME). These companies are all part of the "medical" sector. RXi Pharmaceuticals vs. Its Competitors OS Therapies Eagle Pharmaceuticals Eliem Therapeutics Marinus Pharmaceuticals Hillstream BioPharma Allakos Cara Therapeutics NanoViricides iBio 23andMe OS Therapies (NYSE:OSTX) and RXi Pharmaceuticals (NASDAQ:RXII) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Do institutionals & insiders have more ownership in OSTX or RXII? 9.6% of RXi Pharmaceuticals shares are owned by institutional investors. 13.8% of OS Therapies shares are owned by insiders. Comparatively, 1.0% of RXi Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is OSTX or RXII more profitable? OS Therapies has a net margin of 0.00% compared to RXi Pharmaceuticals' net margin of -4,990.20%. OS Therapies' return on equity of 0.00% beat RXi Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% RXi Pharmaceuticals -4,990.20%-412.15%-179.54% Which has stronger earnings & valuation, OSTX or RXII? OS Therapies has higher earnings, but lower revenue than RXi Pharmaceuticals. OS Therapies is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79M-$0.86-1.91RXi Pharmaceuticals$10K1,073.10-$12.45M-$4.20-0.58 Does the media refer more to OSTX or RXII? In the previous week, OS Therapies had 5 more articles in the media than RXi Pharmaceuticals. MarketBeat recorded 5 mentions for OS Therapies and 0 mentions for RXi Pharmaceuticals. RXi Pharmaceuticals' average media sentiment score of 0.00 beat OS Therapies' score of -0.19 indicating that RXi Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment OS Therapies Neutral RXi Pharmaceuticals Neutral Do analysts rate OSTX or RXII? OS Therapies presently has a consensus target price of $18.00, suggesting a potential upside of 997.56%. Given OS Therapies' stronger consensus rating and higher possible upside, equities research analysts plainly believe OS Therapies is more favorable than RXi Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40RXi Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryOS Therapies beats RXi Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get RXi Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart RXII vs. The Competition Export to ExcelMetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.73M$797.98M$5.53B$9.41BDividend YieldN/A4.84%3.76%4.04%P/E Ratio-0.581.4128.2619.78Price / Sales1,073.1024.93413.4594.56Price / CashN/A19.5635.8558.18Price / Book3.187.058.115.65Net Income-$12.45M-$3.55M$3.25B$257.97M RXi Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXIIRXi PharmaceuticalsN/A$2.45+0.8%N/A-45.6%$10.73M$10K-0.58N/AOSTXOS Therapies2.5165 of 5 stars$1.58-8.7%$18.00+1,039.2%N/A$44.40MN/A-1.84N/AEGRXEagle Pharmaceuticals2.5522 of 5 stars$3.25+8.3%N/A-37.0%$42.21M$257.55M0.00100Gap DownELYMEliem TherapeuticsN/A$1.28+1.6%N/A-79.3%$38.08MN/A-2.429MRNSMarinus Pharmaceuticals2.1017 of 5 stars$0.55-0.2%$3.92+613.3%-61.6%$30.32M$30.99M-0.22110HILSHillstream BioPharmaN/A$1.69-9.1%N/A-55.5%$29.75MN/A-2.351Gap UpALLKAllakos3.4091 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190CARACara Therapeutics0.2589 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumeNNVCNanoViricides0.4362 of 5 stars$1.38+0.3%N/A-20.4%$22.24MN/A-1.9220IBIOiBio1.4397 of 5 stars$0.84+6.7%$4.30+413.4%-66.4%$13.84M$375K0.00100ME23andMeN/A$0.50-35.3%N/A-94.4%$13.36M$208.78M-0.03770Gap DownHigh Trading Volume Related Companies and Tools Related Companies OSTX Alternatives EGRX Alternatives ELYM Alternatives MRNS Alternatives HILS Alternatives ALLK Alternatives CARA Alternatives NNVC Alternatives IBIO Alternatives ME Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXII) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSteve Jobs' Deathbed Secret Finally LeakedLeaked: Jobs’ Final Apple Project Exposed Bloomberg just leaked details of a secret project Steve Jobs set ...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share RXi Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
